Aurelia has been diagnosed with pulmonary hypertension – a rare and life-threatening condition. The family are hoping to get treatment overseas to give her a fighting chance.

Infants born before 24 weeks have survival chances below 50 percent, and about 40 percent of those who survive face long-term ...

Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and ...

Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies October 28, 2025 2:00 ...

Uzbekistani twin brothers, born at 24 weeks of pregnancy weighing 590g and 670g respectively, have reached 100 days healthy ...

The ultra-low weight Uzbek twin brothers, who were born 590g and 670g at 24 weeks of pregnancy in a strange country, Korea, ...

Objectives To evaluate the long-term efficacy of remote ischaemic postconditioning (RIPC) on functional outcomes in patients ...

November is Pulmonary Hypertension Awareness Month, and the American Lung Association, with support from Merck, is raising awareness about one form of the condition: pulmonary arterial hypertension ...

As our real-world evidence continues to grow and access broadens, we continue to believe in YUTREPIA's potential to become the preferred inhaled prostacyclin to treat patients with pulmonary arterial ...

The investments we're making to advance and expand our pipeline are increasingly translating into positive clinical results ...

The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With ...